Literature DB >> 16103884

Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins.

Qunyan Yu1, Maria A Ciemerych, Piotr Sicinski.   

Abstract

D-type cyclins serve as cell cycle recipients of several oncogenic pathways. The specific sequences of the promoters of the cyclin D genes are thought to render particular D-cyclins responsive to specific oncogenic pathways. For instance, the Ras oncogene was postulated to signal through cyclin D1, while Myc can impact the cell cycle machinery by transcriptionally upregulating cyclin D2. In the current study we engineered mouse fibroblasts to express only cyclin D1, only D2, or only D3. These 'single-cyclin' cells allowed us to rigorously test the ability of cyclin D1, D2, or D3, when expressed on their own, to serve as recipients of the Ras- and Myc-driven oncogenic pathways. We found that each of the D-cyclins was sufficient to drive oncogenic proliferation of mouse fibroblasts. This, together with our recent observations that cells lacking all three D-cyclins show greatly reduced susceptibility to the oncogenic action of Ras and Myc, reveals that the Ras and Myc oncogenes can impact the core cell cycle machinery through all three D-cyclins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103884     DOI: 10.1038/sj.onc.1208853

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

Review 1.  MYC: connecting selective transcriptional control to global RNA production.

Authors:  Theresia R Kress; Arianna Sabò; Bruno Amati
Journal:  Nat Rev Cancer       Date:  2015-09-18       Impact factor: 60.716

Review 2.  The role of the RB tumour suppressor pathway in oxidative stress responses in the haematopoietic system.

Authors:  Kay F Macleod
Journal:  Nat Rev Cancer       Date:  2008-09-18       Impact factor: 60.716

3.  Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained.

Authors:  Cassandra J Vandenberg; Paul Waring; Andreas Strasser; Suzanne Cory
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

Review 4.  The history and future of targeting cyclin-dependent kinases in cancer therapy.

Authors:  Uzma Asghar; Agnieszka K Witkiewicz; Nicholas C Turner; Erik S Knudsen
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

5.  Flavin Oxidase-Induced ROS Generation Modulates PKC Biphasic Effect of Resveratrol on Endothelial Cell Survival.

Authors:  Anna Maria Posadino; Roberta Giordo; Annalisa Cossu; Gheyath K Nasrallah; Abdullah Shaito; Haissam Abou-Saleh; Ali H Eid; Gianfranco Pintus
Journal:  Biomolecules       Date:  2019-05-30

6.  Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways.

Authors:  Dai Horiuchi; Noelle E Huskey; Leonard Kusdra; Lara Wohlbold; Karl A Merrick; Chao Zhang; Katelyn J Creasman; Kevan M Shokat; Robert P Fisher; Andrei Goga
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-03       Impact factor: 11.205

Review 7.  Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Authors:  Chenguang Wang; Michael P Lisanti; D Joshua Liao
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

8.  Dampened ERK signaling in hematopoietic progenitor cells in rheumatoid arthritis.

Authors:  Inés Colmegna; Sergey Pryshchep; Hisashi Oishi; Jörg J Goronzy; Cornelia M Weyand
Journal:  Clin Immunol       Date:  2012-01-28       Impact factor: 3.969

Review 9.  Growth factor control of pancreatic islet regeneration and function.

Authors:  Anke Assmann; Charlotte Hinault; Rohit N Kulkarni
Journal:  Pediatr Diabetes       Date:  2008-09-19       Impact factor: 4.866

10.  Signal transduction disturbance related to hepatocarcinogenesis in mouse by prolonged exposure to Nanjing drinking water.

Authors:  Rui Zhang; Jie Sun; Yan Zhang; Shupei Cheng; Xiaowei Zhang
Journal:  Environ Sci Pollut Res Int       Date:  2013-04-17       Impact factor: 4.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.